US StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

Neo-Concept International Group Holdings Limited

1.11

-0.0400-3.48%

Post-market: 1.110.00000.00%16:00 EST

Volume:23.24K

Turnover:25.53K

Market Cap:4.51M

PE:4.08

High:1.14

Open:1.14

Low:1.06

Close:1.15

52wk High:3.40

52wk Low:0.9000

Shares:4.06M

Float Shares:945.20K

Volume Ratio:0.62

T/O Rate:2.46%

Dividend:- -

Dividend Rate:- -

EPS(TTM):0.2723

EPS(LYR):0.2648

ROE:16.08%

ROA:6.19%

PB:0.61

PE(LYR):4.19

Loading ...

Overview Company News Filings

BRIEF-Neo-Concept International Group Holdings Announces Pricing Of Approximately $8.1 Mln Public Offering Of Class A Ordinary Shares

Neo-Concept International Group Holdings Limited Announces Pricing of Approximately US$8.1 Million Public Offering of Class a Ordinary Shares

THOMSON REUTERS

Shell announces commencement of a share buyback programme

Press Release: Shell plc Fourth Quarter 2025 Interim Dividend

PDS Biotech Announces Presentation of Preliminary Results from Phase 2 Study of IL-12 Tumor Targeted Immunocytokine (PDS01ADC) in 3rd Line Metastatic Castration Resistant Prostate Cancer by the NCI

Shell fourth quarter 2025 update note

Neo-Concept International Appoints Pengfei Jiang to Board

Neo-Concept International Group Holdings Limited (NASDAQ:NCI) Surges 45% Yet Its Low P/E Is No Reason For Excitement

Simply Wall St.

Press Release: SHELL PLC THIRD QUARTER 2025 EURO AND GBP EQUIVALENT DIVIDEND PAYMENTS

Plus Therapeutics Highlights Three REYOBIQ™ Clinical Data Presentations at 2025 WFNOS/SNO Annual Meeting

Plus Therapeutics to Present ReSPECT Phase 1 Dose Escalation Study Results for Leptomeningeal Metastases at the 2025 San Antonio Breast Cancer Symposium

Plus Therapeutics Announces Completion of U.S. FDA Meeting on Future Clinical Development Plans for REYOBIQ™ in Leptomeningeal Metastases

Neo-Concept International H1 EPS $0.06 Up From $0.05 YoY, Sales $7.674M Down From $10.150M YoY

Press Release: Neo-Concept International Group Holdings Limited Announces First Half 2025 Unaudited Financial Results

National Cancer Institute Broadens Partnership with Medidata to Bring Unmatched Continuity of Medical and Clinical Data for Lead Protocol Organizations

Press Release: PDS Biotech Reports Third Quarter 2025 Financial Results and Provides Clinical Programs Update

PDS Biotechnology Announces Translational Data Showing Strong Immunological and Clinical Activity of PDS0101 and PDS01ADC Presented at SITC 2025

Press Release: ORYZON Reports Financial Results and Corporate Update for Quarter Ended September 30, 2025

BriaCell Presents Robust Anti-Cancer Activity of Bria-OTS+™ at SITC 2025

Complete Tumor Regressions Observed in Preclinical Models with Co-administration of Cyncado’s A2B and A2A Receptor Antagonists and Cancer Vaccines

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/stock/NCI/news"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"NCI","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"NCI\",,,,,undefined,":{"symbol":"NCI","market":"US","secType":"STK","nameCN":"Neo-Concept International Group Holdings Limited","latestPrice":1.11,"timestamp":1770670800000,"preClose":1.15,"halted":0,"volume":23238,"hourTrading":{"tag":"盘后","latestPrice":1.11,"preClose":1.11,"latestTime":"16:00 EST","volume":30,"amount":33.300000000000004,"timestamp":1770670801610,"change":0,"changeRate":0,"amplitude":0},"delay":0,"changeRate":-0.034782608695652015,"floatShares":945200,"shares":4064000,"eps":0.272333,"marketStatus":"Closed","change":-0.04,"latestTime":"02-09 16:00:00 EST","open":1.1398,"high":1.14,"low":1.06,"amount":25533.5392,"amplitude":0.069565,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":0.272333,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1770714000000},"marketStatusCode":5,"adr":0,"adrRate":0,"listingDate":1713844800000,"exchange":"NASDAQ","adjPreClose":1.15,"preHourTrading":{"tag":"盘前","latestPrice":1.05,"preClose":1.14,"latestTime":"09:23 EST","volume":53,"amount":55.7399993,"timestamp":1770647004991,"change":-0.09,"changeRate":-0.078947,"amplitude":0.078947},"postHourTrading":{"tag":"盘后","latestPrice":1.11,"preClose":1.11,"latestTime":"16:00 EST","volume":30,"amount":33.300000000000004,"timestamp":1770670801610,"change":0,"changeRate":0,"amplitude":0},"volumeRatio":0.618954},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"NCI\",,,,,undefined,":{"symbol":"NCI","floatShares":945200,"roa":"6.19%","roe":"16.08%","lyrEps":0.264768,"volumeRatio":0.618954,"shares":4064000,"dividePrice":0,"high":1.14,"amplitude":0.069565,"preClose":1.15,"low":1.06,"week52Low":0.9,"pbRate":"0.61","psRate":"0.16","week52High":3.4,"institutionHeld":0.7857,"latestPrice":1.11,"eps":0.272333,"divideRate":0,"volume":23238,"delay":0,"ttmEps":0.272333,"open":1.1398,"prevYearClose":1.13,"prevWeekClose":1.15,"prevMonthClose":1.25,"prevQuarterClose":1.13,"fiveDayClose":1.3,"twentyDayClose":1.27,"sixtyDayClose":1.1},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/NCI\",params:#limit:5,,,undefined,":[{"market":"US","date":"2025-06-16","symbol":"NCI","defaultRemindTime":1750080600000,"type":"split","dateTimestamp":1750046400000,"forFactor":5,"toFactor":1,"ratio":5}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"NCI\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"NCI\",market:\"US\",delay:false,,,undefined,":{},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/NCI\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"NCI","date":"2026-02-06","current":4.075892,"percent":0.060134,"low":-615.963293,"twenty":5.480595,"median":8.444427,"eighty":20.045692,"high":50.092968,"avg":7.418394,"sd":38.223973,"marketCap":4483424},"quantilePoints":[{"date":"2024-04-26","current":-152.934443,"twenty":-421.533502,"median":-222.424043,"eighty":-152.416021,"marketCap":47955200},{"date":"2024-05-03","current":-75.704037,"twenty":-208.526123,"median":-121.807344,"eighty":-81.702314,"marketCap":23774400},{"date":"2024-05-10","current":-74.39805,"twenty":-152.15681,"median":-81.565326,"eighty":-71.297323,"marketCap":23368000},{"date":"2024-05-17","current":36.631419,"twenty":-133.739762,"median":-74.39805,"eighty":-23.514082,"marketCap":20726400},{"date":"2024-05-24","current":30.19238,"twenty":-105.051475,"median":-71.169081,"eighty":36.421773,"marketCap":17068800},{"date":"2024-05-31","current":25.951993,"twenty":-89.228644,"median":-65.79629,"eighty":35.854613,"marketCap":14650720},{"date":"2024-06-07","current":26.211896,"twenty":-81.702314,"median":25.015338,"eighty":34.642796,"marketCap":14813280},{"date":"2024-06-14","current":29.519581,"twenty":-78.809845,"median":25.103888,"eighty":32.998302,"marketCap":16682720},{"date":"2024-06-21","current":25.962557,"twenty":-75.44284,"median":25.889128,"eighty":31.491027,"marketCap":14685264},{"date":"2024-06-28","current":22.645555,"twenty":-74.134092,"median":25.192438,"eighty":30.05782,"marketCap":12803632},{"date":"2024-07-05","current":22.365126,"twenty":-73.07826,"median":25.015338,"eighty":29.519581,"marketCap":12639040},{"date":"2024-07-12","current":23.313894,"twenty":-71.810291,"median":24.273321,"eighty":28.980357,"marketCap":13183616},{"date":"2024-07-19","current":21.771249,"twenty":-70.527871,"median":24.005484,"eighty":28.783514,"marketCap":12305792},{"date":"2024-07-26","current":19.871565,"twenty":-67.981499,"median":23.548157,"eighty":28.579978,"marketCap":11236980},{"date":"2024-08-02","current":17.380948,"twenty":-63.611082,"median":23.313894,"eighty":28.402846,"marketCap":9828784},{"date":"2024-08-09","current":14.824233,"twenty":14.824233,"median":22.666232,"eighty":28.339976,"marketCap":8393176},{"date":"2024-08-16","current":14.891311,"twenty":14.824233,"median":22.428658,"eighty":26.393551,"marketCap":8432800},{"date":"2024-08-23","current":16.505019,"twenty":14.824233,"median":21.843651,"eighty":26.38192,"marketCap":9347200},{"date":"2024-08-30","current":15.221442,"twenty":14.891311,"median":21.615595,"eighty":26.235018,"marketCap":8617712},{"date":"2024-09-06","current":14.786956,"twenty":14.816778,"median":21.03365,"eighty":26.21652,"marketCap":8375904},{"date":"2024-09-13","current":18.291286,"twenty":14.783803,"median":19.997266,"eighty":26.012425,"marketCap":10355072},{"date":"2024-09-20","current":25.287335,"twenty":14.816778,"median":19.871565,"eighty":26.012425,"marketCap":14325600},{"date":"2024-09-27","current":18.961375,"twenty":14.877895,"median":19.084343,"eighty":25.954106,"marketCap":10769600},{"date":"2024-10-04","current":21.913118,"twenty":15.042266,"median":20.067523,"eighty":26.126798,"marketCap":12454128},{"date":"2024-10-11","current":22.176748,"twenty":15.165199,"median":20.049509,"eighty":25.99115,"marketCap":12598400},{"date":"2024-10-18","current":32.898839,"twenty":15.206634,"median":20.803771,"eighty":26.126798,"marketCap":18694400},{"date":"2024-10-25","current":23.358148,"twenty":15.219487,"median":21.352319,"eighty":26.21652,"marketCap":13270992},{"date":"2024-11-01","current":27.487373,"twenty":15.232907,"median":21.771249,"eighty":26.583872,"marketCap":15603728},{"date":"2024-11-08","current":26.826792,"twenty":15.38624,"median":21.882165,"eighty":26.827702,"marketCap":15231872},{"date":"2024-11-15","current":22.217928,"twenty":15.464941,"median":22.207911,"eighty":26.517352,"marketCap":12598400},{"date":"2024-11-22","current":19.532206,"twenty":15.526206,"median":22.192329,"eighty":26.402839,"marketCap":11076432},{"date":"2024-11-29","current":19.712189,"twenty":15.580772,"median":21.882165,"eighty":26.386572,"marketCap":11184128},{"date":"2024-12-06","current":18.691913,"twenty":15.639248,"median":21.771249,"eighty":26.293779,"marketCap":10607040},{"date":"2024-12-13","current":18.611126,"twenty":15.691094,"median":21.352319,"eighty":26.221145,"marketCap":10566400},{"date":"2024-12-20","current":7.102414,"twenty":15.639248,"median":20.803771,"eighty":26.151136,"marketCap":10058400},{"date":"2024-12-27","current":7.471029,"twenty":15.444399,"median":20.742686,"eighty":26.108587,"marketCap":10592816},{"date":"2025-01-03","current":10.196837,"twenty":15.213623,"median":20.067523,"eighty":26.07693,"marketCap":14427200},{"date":"2025-01-10","current":10.034934,"twenty":14.891311,"median":20.043836,"eighty":25.962557,"marketCap":14183360},{"date":"2025-01-17","current":9.907617,"twenty":14.749465,"median":19.895277,"eighty":25.951993,"marketCap":14008608},{"date":"2025-01-24","current":9.563114,"twenty":13.631492,"median":19.697706,"eighty":25.85141,"marketCap":13512800},{"date":"2025-01-31","current":8.48834,"twenty":10.018271,"median":19.532206,"eighty":25.746589,"marketCap":11988800},{"date":"2025-02-07","current":7.730432,"twenty":9.882149,"median":19.361654,"eighty":25.46422,"marketCap":10919968},{"date":"2025-02-14","current":7.130829,"twenty":9.483748,"median":19.090069,"eighty":25.309589,"marketCap":10081768},{"date":"2025-02-21","current":7.314786,"twenty":8.865676,"median":18.969464,"eighty":25.26403,"marketCap":10361168},{"date":"2025-02-28","current":5.889209,"twenty":8.594149,"median":18.858804,"eighty":25.21486,"marketCap":8333232},{"date":"2025-03-07","current":6.028973,"twenty":8.100004,"median":18.691913,"eighty":25.173677,"marketCap":8536432},{"date":"2025-03-14","current":5.598897,"twenty":7.846255,"median":18.496802,"eighty":25.10156,"marketCap":7926832},{"date":"2025-03-21","current":5.968988,"twenty":7.540872,"median":18.291286,"eighty":25.033931,"marketCap":8451088},{"date":"2025-03-28","current":7.03753,"twenty":7.389256,"median":18.105135,"eighty":24.856699,"marketCap":9956800},{"date":"2025-04-04","current":6.201809,"twenty":7.119463,"median":17.654152,"eighty":24.701604,"marketCap":8778240},{"date":"2025-04-11","current":6.159082,"twenty":7.009081,"median":17.557752,"eighty":24.560727,"marketCap":8737600},{"date":"2025-04-17","current":6.305413,"twenty":6.892251,"median":17.348506,"eighty":24.472151,"marketCap":8938768},{"date":"2025-04-25","current":5.299322,"twenty":6.518915,"median":16.836333,"eighty":24.40328,"marketCap":7518400},{"date":"2025-05-02","current":4.437465,"twenty":6.31653,"median":16.510738,"eighty":24.325687,"marketCap":6301232},{"date":"2025-05-09","current":5.171449,"twenty":6.285391,"median":16.156269,"eighty":24.224718,"marketCap":7317232},{"date":"2025-05-16","current":6.695699,"twenty":6.181855,"median":15.685852,"eighty":24.063819,"marketCap":6908800},{"date":"2025-05-23","current":7.021962,"twenty":6.235146,"median":15.538955,"eighty":24.008491,"marketCap":7233920},{"date":"2025-05-30","current":8.164705,"twenty":6.285272,"median":15.423857,"eighty":24.005032,"marketCap":8397532},{"date":"2025-06-06","current":8.847265,"twenty":6.289683,"median":15.216555,"eighty":23.931629,"marketCap":9092468},{"date":"2025-06-13","current":8.179292,"twenty":6.306628,"median":15.080005,"eighty":23.644242,"marketCap":8402196},{"date":"2025-06-20","current":10.670242,"twenty":6.311489,"median":14.824233,"eighty":23.64022,"marketCap":10960400},{"date":"2025-06-27","current":11.716334,"twenty":6.315883,"median":14.760327,"eighty":23.456094,"marketCap":12034985},{"date":"2025-07-03","current":10.216346,"twenty":6.317177,"median":14.71349,"eighty":23.384943,"marketCap":10494000},{"date":"2025-07-11","current":10.261711,"twenty":6.410478,"median":11.716334,"eighty":23.359949,"marketCap":10540640},{"date":"2025-07-18","current":9.808428,"twenty":6.454657,"median":10.875077,"eighty":23.322745,"marketCap":10077038},{"date":"2025-07-25","current":9.671429,"twenty":6.462794,"median":10.624987,"eighty":23.130117,"marketCap":9934320},{"date":"2025-08-01","current":8.89955,"twenty":6.57431,"median":10.442049,"eighty":23.054884,"marketCap":9141440},{"date":"2025-08-08","current":8.26371,"twenty":6.676961,"median":10.261711,"eighty":22.850835,"marketCap":8488480},{"date":"2025-08-15","current":8.020396,"twenty":6.711807,"median":10.206559,"eighty":22.709857,"marketCap":8255280},{"date":"2025-08-22","current":7.944228,"twenty":6.718226,"median":10.054926,"eighty":22.653826,"marketCap":8198379},{"date":"2025-08-29","current":7.484931,"twenty":6.73937,"median":9.97069,"eighty":22.584141,"marketCap":7742240},{"date":"2025-09-05","current":9.159836,"twenty":6.821347,"median":9.934593,"eighty":22.562922,"marketCap":9467920},{"date":"2025-09-12","current":9.23611,"twenty":6.883125,"median":9.907617,"eighty":22.500907,"marketCap":9561200},{"date":"2025-09-19","current":8.862273,"twenty":6.893296,"median":9.771265,"eighty":22.442063,"marketCap":9188080},{"date":"2025-09-26","current":7.431141,"twenty":6.901678,"median":9.711704,"eighty":22.390539,"marketCap":7701314},{"date":"2025-10-03","current":7.413811,"twenty":6.942194,"median":9.659792,"eighty":22.276807,"marketCap":7680994},{"date":"2025-10-10","current":7.489961,"twenty":6.99974,"median":9.578721,"eighty":22.211918,"marketCap":7762274},{"date":"2025-10-17","current":7.128574,"twenty":6.974212,"median":9.51173,"eighty":22.189213,"marketCap":7396512},{"date":"2025-10-24","current":6.854291,"twenty":6.883125,"median":9.462569,"eighty":22.01857,"marketCap":7112031},{"date":"2025-10-31","current":6.186973,"twenty":6.854004,"median":9.33225,"eighty":21.875975,"marketCap":6421148},{"date":"2025-11-07","current":4.741629,"twenty":6.765339,"median":9.223624,"eighty":21.842138,"marketCap":4917461},{"date":"2025-11-14","current":4.19042,"twenty":6.696493,"median":9.126243,"eighty":21.797185,"marketCap":4348499},{"date":"2025-11-21","current":3.92273,"twenty":6.462068,"median":9.081059,"eighty":21.677857,"marketCap":4064018},{"date":"2025-11-28","current":4.258196,"twenty":6.343606,"median":9.054357,"eighty":21.613946,"marketCap":4754901},{"date":"2025-12-05","current":4.259674,"twenty":6.293615,"median":8.88422,"eighty":21.40415,"marketCap":4754901},{"date":"2025-12-12","current":4.514242,"twenty":6.192907,"median":8.860854,"eighty":21.069359,"marketCap":5039382},{"date":"2025-12-19","current":5.42375,"twenty":6.139436,"median":8.843088,"eighty":20.941698,"marketCap":6055386},{"date":"2025-12-26","current":4.946749,"twenty":6.043228,"median":8.826007,"eighty":20.793652,"marketCap":5527064},{"date":"2026-01-02","current":4.114478,"twenty":6.028003,"median":8.79797,"eighty":20.753178,"marketCap":4592340},{"date":"2026-01-09","current":4.520095,"twenty":5.916655,"median":8.737897,"eighty":20.742686,"marketCap":5039382},{"date":"2026-01-16","current":4.304481,"twenty":5.809528,"median":8.606,"eighty":20.122966,"marketCap":4795541},{"date":"2026-01-23","current":4.012602,"twenty":5.729394,"median":8.586921,"eighty":20.078612,"marketCap":4470419},{"date":"2026-01-30","current":3.980203,"twenty":5.598444,"median":8.507076,"eighty":20.055999,"marketCap":4429779},{"date":"2026-02-06","current":4.032698,"twenty":5.480595,"median":8.444427,"eighty":20.045692,"marketCap":4483424}],"updateTime":1770683981407},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"NCI\",pageSize:20,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2610695798","title":"BRIEF-Neo-Concept International Group Holdings Announces Pricing Of Approximately $8.1 Mln Public Offering Of Class A Ordinary Shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2610695798","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2610695798?lang=en_us&edition=fundamental","pubTime":"2026-02-10 10:03","pubTimestamp":1770688989,"startTime":"0","endTime":"0","summary":"BRIEF-Neo-Concept International Group Holdings Announces Pricing Of Approximately $8.1 Mln Public Offering Of Class A Ordinary SharesFeb 9 (Reuters) - Neo-Concept International Group Holdings Ltd NCI.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260210:nFWN3Z51DJ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4202","NCI"],"gpt_icon":0},{"id":"2610369520","title":"Neo-Concept International Group Holdings Limited Announces Pricing of Approximately US$8.1 Million Public Offering of Class a Ordinary Shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2610369520","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2610369520?lang=en_us&edition=fundamental","pubTime":"2026-02-10 10:01","pubTimestamp":1770688877,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260210:nFWN3Z51DJ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["NCI","BK4202"],"gpt_icon":0},{"id":"2609326139","title":"Shell announces commencement of a share buyback programme","url":"https://stock-news.laohu8.com/highlight/detail?id=2609326139","media":"GlobeNewswire","labels":["shareholding","buyback"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2609326139?lang=en_us&edition=fundamental","pubTime":"2026-02-05 15:03","pubTimestamp":1770274980,"startTime":"0","endTime":"0","summary":"Shell plc Shell announces commencement of a share buyback programme February 5, 2026 Shell plc (the ‘Company’) today announces the commencement of a $3.5 billion share buyback programme covering an ag","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/02/05/3232673/0/en/Shell-announces-commencement-of-a-share-buyback-programme.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding,buyback","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4156","BK4202","NCI"],"gpt_icon":0},{"id":"2609326355","title":"Press Release: Shell plc Fourth Quarter 2025 Interim Dividend","url":"https://stock-news.laohu8.com/highlight/detail?id=2609326355","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2609326355?lang=en_us&edition=fundamental","pubTime":"2026-02-05 15:02","pubTimestamp":1770274920,"startTime":"0","endTime":"0","summary":"London, February 5, 2026 - The Board of Shell plc   today announced an interim dividend in respect of the fourth quarter of 2025 of US$ 0.372 per ordinary share.Details relating to the fourth quarter 2025 interim dividend. Shareholders will be able to elect to receive their dividends in US dollars, euros or pounds sterling.An alternative 'Electronic Election Entitlement'  process is available in CREST for dividends with options elections.Absent any valid election to the contrary, persons holding their ordinary shares through Euroclear Nederland will receive their dividends in euros.Absent any valid election to the contrary, shareholders  and persons holding their shares through the Shell Corporate Nominee will receive their dividends in pounds sterling.Each ADS represents two ordinary shares. ADSs are evidenced by an American Depositary Receipt  certificate. In many cases the terms ADR and ADS are used interchangeably.Dividend timetable for the fourth quarter 2025 interim dividend. If ","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4202","LU0098860793.USD","LU2236285917.USD","NCI","BK4588","LU0300736062.USD","LU0278409577.USD","BK4201","LU1162221912.USD","SHEL","BK4585","LU0300736492.USD","LU0320765646.SGD"],"gpt_icon":0},{"id":"2606166712","title":"PDS Biotech Announces Presentation of Preliminary Results from Phase 2 Study of IL-12 Tumor Targeted Immunocytokine (PDS01ADC) in 3rd Line Metastatic Castration Resistant Prostate Cancer by the NCI","url":"https://stock-news.laohu8.com/highlight/detail?id=2606166712","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2606166712?lang=en_us&edition=fundamental","pubTime":"2026-01-28 21:45","pubTimestamp":1769607900,"startTime":"0","endTime":"0","summary":"NCI-Led Study Shows Median PFS of 9.6 MonthsResults Presented at AACR Special Conference on Innovations in Prostate Cancer PRINCETON, N.J., Jan.  28, 2026  (GLOBE NEWSWIRE) -- PDS Biotechnology Corpor","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/01/28/3227632/37149/en/PDS-Biotech-Announces-Presentation-of-Preliminary-Results-from-Phase-2-Study-of-IL-12-Tumor-Targeted-Immunocytokine-PDS01ADC-in-3rd-Line-Metastatic-Castration-Resistant-Prostate-Ca.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4588","01336","NCI","BK1550","BK1184","BK4231","ADC","PDS","LU0572940350.SGD","LU0572939691.SGD","BK4092","LU0264606111.USD","BK1584","BK4202","BK4585","LABU","BK4080"],"gpt_icon":0},{"id":"2601353713","title":"Shell fourth quarter 2025 update note","url":"https://stock-news.laohu8.com/highlight/detail?id=2601353713","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2601353713?lang=en_us&edition=fundamental","pubTime":"2026-01-08 15:00","pubTimestamp":1767855600,"startTime":"0","endTime":"0","summary":"The following is an update to the fourth quarter 2025 outlook and gives an overview of our current expectations for the fourth quarter. Outlooks presented may vary from the actual fourth quarter 2025 ","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/01/08/3215055/0/en/Shell-fourth-quarter-2025-update-note.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NCI","BK4006","BK4561","MT","BK4202"],"gpt_icon":0},{"id":"2592891349","title":"Neo-Concept International Appoints Pengfei Jiang to Board","url":"https://stock-news.laohu8.com/highlight/detail?id=2592891349","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2592891349?lang=en_us&edition=fundamental","pubTime":"2025-12-17 22:01","pubTimestamp":1765980064,"startTime":"0","endTime":"0","summary":"Neo-Concept International Group Holdings Ltd. has appointed Mr. Pengfei Jiang as a Director of the Board, effective December 16, 2025. Mr. Jiang is currently the General Manager of Guangzhou Nanbeiji Technology Development Co., Ltd., and brings experience in corporate strategy, industry research, and investment project evaluation.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Neo-Concept International Group Holdings Ltd. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on December 17, 2025, and is solely responsible for the information contained therein.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251217:nNDL43pZMj:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK0004","BK0209","NCI","BK4202","BK0210","600539"],"gpt_icon":0},{"id":"2591982752","title":"Neo-Concept International Group Holdings Limited (NASDAQ:NCI) Surges 45% Yet Its Low P/E Is No Reason For Excitement","url":"https://stock-news.laohu8.com/highlight/detail?id=2591982752","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2591982752?lang=en_us&edition=fundamental","pubTime":"2025-12-16 20:55","pubTimestamp":1765889716,"startTime":"0","endTime":"0","summary":"Those holding Neo-Concept International Group Holdings Limited ( NASDAQ:NCI ) shares would be relieved that the share...","market":"hk","thumbnail":"https://images.simplywall.st/asset/industry/4131000-choice2-main-header/1585186733037","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/4131000-choice2-main-header/1585186733037"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/consumer-durables/nasdaq-nci/neo-concept-international-group-holdings/news/neo-concept-international-group-holdings-limited-nasdaqnci-s-1","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/consumer-durables/nasdaq-nci/neo-concept-international-group-holdings/news/neo-concept-international-group-holdings-limited-nasdaqnci-s-1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["QLD","USJW.SI","TSYW.SI","NCI","NVIW.SI","QID","01336","NQmain","TQQQ","LU0264606111.USD",".IXIC","BK1550","LU0572939691.SGD","BK1584","LU0572940350.SGD","SQQQ","USAW.SI","BK4202","BK1184","MNQmain","PSQ"],"gpt_icon":1},{"id":"2589382559","title":"Press Release: SHELL PLC THIRD QUARTER 2025 EURO AND GBP EQUIVALENT DIVIDEND PAYMENTS","url":"https://stock-news.laohu8.com/highlight/detail?id=2589382559","media":"Dow Jones","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2589382559?lang=en_us&edition=fundamental","pubTime":"2025-12-08 15:00","pubTimestamp":1765177200,"startTime":"0","endTime":"0","summary":"The Board of Shell plc today announced the pounds sterling and euro equivalent dividend payments in respect of the third quarter 2025 interim dividend, which was announced on October 30, 2025 at US$0.358 per ordinary share.Shareholders have been able to elect to receive their dividends in US dollars, euros or pounds sterling. Holders of ordinary shares who have validly submitted US dollars, euros or pounds sterling currency elections by November 28, 2025 will be entitled to a dividend of US$0.358, EUR0.3070 or 26.85p per ordinary share, respectively.Euro and pounds sterling dividends payable in cash have been converted from US dollars based on an average of market exchange rates over the three dealing days from December 3 to December 5, 2025. This dividend will be payable on December 18, 2025 to those members whose names were on the Register of Members on November 14, 2025.","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0278409577.USD","LU0300736062.USD","BK4201","BK4588","LU0098860793.USD","BK4585","LU1162221912.USD","LU2236285917.USD","LU0300736492.USD","LU0320765646.SGD","BK4202","SHEL","NCI"],"gpt_icon":0},{"id":"2588881197","title":"Plus Therapeutics Highlights Three REYOBIQ™ Clinical Data Presentations at 2025 WFNOS/SNO Annual Meeting","url":"https://stock-news.laohu8.com/highlight/detail?id=2588881197","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2588881197?lang=en_us&edition=fundamental","pubTime":"2025-12-04 20:30","pubTimestamp":1764851400,"startTime":"0","endTime":"0","summary":"Cohort 1 data from multiple dose ReSPECT- Leptomeningeal Metastases (LM) trial showed no dosage limiting toxicity ReSPECT-Glioblastoma (GBM) trial of REYOBIQ as a novel therapeutic for recurrent GBM d","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/12/04/3199678/0/en/Plus-Therapeutics-Highlights-Three-REYOBIQ-Clinical-Data-Presentations-at-2025-WFNOS-SNO-Annual-Meeting.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4202","NCI","BK4539","BK4139","BK4007","CNS","LENZ","BK4135"],"gpt_icon":0},{"id":"2588727632","title":"Plus Therapeutics to Present ReSPECT Phase 1 Dose Escalation Study Results for Leptomeningeal Metastases at the 2025 San Antonio Breast Cancer Symposium","url":"https://stock-news.laohu8.com/highlight/detail?id=2588727632","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2588727632?lang=en_us&edition=fundamental","pubTime":"2025-12-01 20:30","pubTimestamp":1764592200,"startTime":"0","endTime":"0","summary":"Study findings to be featured in a poster spotlight presentationHOUSTON, Dec.  01, 2025  (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq:PSTV) (the “Company”), a clinical-stage pharmaceutical comp","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/12/01/3196910/0/en/Plus-Therapeutics-to-Present-ReSPECT-Phase-1-Dose-Escalation-Study-Results-for-Leptomeningeal-Metastases-at-the-2025-San-Antonio-Breast-Cancer-Symposium.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4135","CNS","BK4539","NCI","LENZ","BK4139","BK4007","BK4202"],"gpt_icon":0},{"id":"2585643714","title":"Plus Therapeutics Announces Completion of U.S. FDA Meeting on Future Clinical Development Plans for REYOBIQ™ in Leptomeningeal Metastases","url":"https://stock-news.laohu8.com/highlight/detail?id=2585643714","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2585643714?lang=en_us&edition=fundamental","pubTime":"2025-11-24 20:30","pubTimestamp":1763987400,"startTime":"0","endTime":"0","summary":"HOUSTON, Nov.  24, 2025  (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq:PSTV) (the “Company”), a healthcare company developing and commercializing precision diagnostics and radiopharmaceuticals f","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/11/24/3193399/0/en/Plus-Therapeutics-Announces-Completion-of-U-S-FDA-Meeting-on-Future-Clinical-Development-Plans-for-REYOBIQ-in-Leptomeningeal-Metastases.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LENZ","CNS","BK4007","NCI","BK4135","BK4139","BK4202","BK4539"],"gpt_icon":0},{"id":"2585141798","title":"Neo-Concept International H1 EPS $0.06 Up From $0.05 YoY, Sales $7.674M Down From $10.150M YoY","url":"https://stock-news.laohu8.com/highlight/detail?id=2585141798","media":"Benzinga","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2585141798?lang=en_us&edition=fundamental","pubTime":"2025-11-21 23:12","pubTimestamp":1763737971,"startTime":"0","endTime":"0","summary":"Neo-Concept International (NASDAQ:NCI) reported quarterly earnings of $0.06 per share. This is a 20 percent increase over earnings of $0.05 per share from the same period last year.  The company reported $7.674 million","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/earnings/25/11/49003998/neo-concept-international-h1-eps-0-06-up-from-0-05-yoy-sales-7-674m-down-from-10-150m-yoy","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SQQQ","TSYW.SI",".IXIC","QID","NCI","BK4202","QLD","TQQQ","USJW.SI","MNQmain","NVIW.SI","USAW.SI","PSQ","NQmain"],"gpt_icon":0},{"id":"2585149782","title":"Press Release: Neo-Concept International Group Holdings Limited Announces First Half 2025 Unaudited Financial Results","url":"https://stock-news.laohu8.com/highlight/detail?id=2585149782","media":"Dow Jones","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2585149782?lang=en_us&edition=fundamental","pubTime":"2025-11-21 22:40","pubTimestamp":1763736000,"startTime":"0","endTime":"0","summary":"Hong Kong, Nov. 21, 2025  -- Neo-Concept International Group Holdings Limited  , today announced its unaudited financial results for the six months ended June 30, 2025.-- Revenue was approximately HK$60.2 million  for the six. months ended June 30, 2025, representing a decrease of approximately. -- Net income was approximately HK$2.0 million  for the six. months ended June 30, 2025 (2024: net income approximately HK$1.4. Other income, net. Other income representing agency fee received decreased approximately 47.1% from HK$2.4 million for the six months ended June 30, 2024 to HK$1.2 million  for the six months ended June 30, 2025, the agency fee represents for liaison with customers of the related party based in United Kingdom including making price quotation, handling purchase order, after-sales service, etc. The primary reason for the decrease was a decline in sales activity of the related party in United Kingdom, which adversely impacted the agency fee.Income tax expense. Income tax ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4202","NCI"],"gpt_icon":0},{"id":"2585987481","title":"National Cancer Institute Broadens Partnership with Medidata to Bring Unmatched Continuity of Medical and Clinical Data for Lead Protocol Organizations","url":"https://stock-news.laohu8.com/highlight/detail?id=2585987481","media":"prnewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2585987481?lang=en_us&edition=fundamental","pubTime":"2025-11-21 11:19","pubTimestamp":1763695140,"startTime":"0","endTime":"0","summary":"The Medidata Data Experience offering will enable the National Cancer Institute Lead Protocol Organizations to expedite the development of life-saving medicines for patients. About MedidataMedidata is powering smarter treatments and healthier people through digital solutions to support clinical trials. Celebrating 25 years of ground-breaking technological innovation across more than 36,000 trials and 11 million patients, Medidata offers industry-leading expertise, analytics-powered insights, and one of the largest clinical trial data sets in the industry. More than 1 million registered users across approximately 2,300 customers trust Medidata's seamless, end-to-end platform to improve patient experiences, accelerate clinical breakthroughs, and bring therapies to market faster. A Dassault Systèmes brand , Medidata is headquartered in New York City and has been recognized as a Leader by Everest Group and IDC. Discover more at www.medidata.com. Listen to our latest pod","market":"hk","thumbnail":"https://mma.prnewswire.com/media/2699901/Medidata_Logo.jpg?w=300","type":0,"news_type":0,"thumbnails":["https://mma.prnewswire.com/media/2699901/Medidata_Logo.jpg?w=300"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.prnewswire.com/apac/news-releases/national-cancer-institute-broadens-partnership-with-medidata-to-bring-unmatched-continuity-of-medical-and-clinical-data-for-lead-protocol-organizations-302622705.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NHLD","BK4202","NCI"],"gpt_icon":0},{"id":"2583567674","title":"Press Release: PDS Biotech Reports Third Quarter 2025 Financial Results and Provides Clinical Programs Update","url":"https://stock-news.laohu8.com/highlight/detail?id=2583567674","media":"Dow Jones","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2583567674?lang=en_us&edition=fundamental","pubTime":"2025-11-13 20:30","pubTimestamp":1763037000,"startTime":"0","endTime":"0","summary":"Phase 2 Results Lead Company to Seek Expedited Approval Pathway in Ongoing. Conference Call and Webcast today at 8:00 a.m. Eastern Time. PRINCETON, N.J., Nov. 13, 2025  -- PDS Biotechnology Corporation  , a late-stage immunotherapy company focused on transforming how the immune system targets and kills cancers, today provided a business update, reported financial results for the third quarter ended September 30, 2025, and provided a clinical programs update.\"Our request to meet with the FDA to propose an amendment to our ongoing VERSATILE-003 Phase 3 trial represents the culmination of the encouraging data from our now completed VERSATILE-002 trial\", said Frank Bedu-Addo, PhD, President and Chief Executive Officer of PDS Biotech. \"We believe the positive PFS data offers an important opportunity to shorten the trial duration and time to regulatory submission while maintaining mOS as the endpoint for full FDA approval. Importantly, we believe this approach may also accelerate the availab","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4099","BK4585","BK4555","BK4139","BK4092","BK4202","NCI","03160","BK4231","PDS","R","BK4022","SITC","ADC","TM","BK4232","BK4588","PDSB","BK4080","BK4604"],"gpt_icon":0},{"id":"2582391872","title":"PDS Biotechnology Announces Translational Data Showing Strong Immunological and Clinical Activity of PDS0101 and PDS01ADC Presented at SITC 2025","url":"https://stock-news.laohu8.com/highlight/detail?id=2582391872","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2582391872?lang=en_us&edition=fundamental","pubTime":"2025-11-10 21:30","pubTimestamp":1762781400,"startTime":"0","endTime":"0","summary":"Translational study shows that multiple immunological biomarkers predict the clinical activity of PDS0101 combination therapyPDS01ADC reprograms natural killer (NK) cells to possess characteristics th","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/11/10/3184578/37149/en/PDS-Biotechnology-Announces-Translational-Data-Showing-Strong-Immunological-and-Clinical-Activity-of-PDS0101-and-PDS01ADC-Presented-at-SITC-2025.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PDS","BK4550","LU1066051811.HKD","LU1989771016.USD","SG9999014542.SGD","BK4533","BK4588","IE00BLSP4452.SGD","LU2361045086.USD","LU1699723380.USD","IE0003851619.USD","ADC","BK4534","LU1023059063.AUD","IE00B2B36J28.USD","LU1929549753.HKD","LU2361044865.SGD","SG9999002232.USD","BK4202","01308","CCR","BK4092","SG9999015341.SGD","SGXZ57979304.SGD","IE00BFTCPJ56.SGD","IE000M9KFDE8.USD","LU0208291251.USD","LU0265550946.USD","LU1934455863.HKD","LU2112291526.USD","MRK","SG9999015358.SGD","LU2361044949.HKD","LU1069347547.HKD","LU0211331839.USD","NCI","BK4559","LU0234572021.USD","LU1917777945.USD","SG9999014567.USD","SITC","LU2023250843.SGD","LU1430594728.SGD","IE00BYQNZ168.SGD","LU0070302665.USD","LU1974910355.USD","SG9999002224.SGD","LU0320765646.SGD","LU0861579265.USD"],"gpt_icon":0},{"id":"2581266888","title":"Press Release: ORYZON Reports Financial Results and Corporate Update for Quarter Ended September 30, 2025","url":"https://stock-news.laohu8.com/highlight/detail?id=2581266888","media":"Dow Jones","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2581266888?lang=en_us&edition=fundamental","pubTime":"2025-11-07 21:01","pubTimestamp":1762520460,"startTime":"0","endTime":"0","summary":"-- The net result as of September 30, 2025 improved by $1.1M compared to. September 2024, following termination of a Convertible Bonds financing. --    Received feedback from the FDA on Phase III PORTICO-2        --    Positive data in 1L AML to be presented at ASH with. trial in BPD; Company to revise protocol and resubmit                               100% ORR . --    Reinforcing company's clinical, strategy and              --    Positive data in R/R FLT3+ AML to be presented at. \"We have secured over $60 million in the first half of 2025, marking a significant turnaround for Oryzon,\" said Dr. Carlos Buesa, Oryzon's Chief Executive Officer. \"These proceeds enable us to advance our clinical programs with a renewed strategic focus on CNS, particularly in our studies in BPD, schizophrenia, and ASD.\". \"Following the FDA's feedback, the Company has strengthened its clinical, strategic, and regulatory teams by incorporating highly experienced professionals with deep expertise in late-stag","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4161","OS","ORR","ASH","BK4202","LU2463526074.USD","CR","BK4109","BK4097","NCI"],"gpt_icon":0},{"id":"2581888267","title":"BriaCell Presents Robust Anti-Cancer Activity of Bria-OTS+™ at SITC 2025","url":"https://stock-news.laohu8.com/highlight/detail?id=2581888267","media":"GlobeNewswire","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2581888267?lang=en_us&edition=fundamental","pubTime":"2025-11-07 20:30","pubTimestamp":1762518600,"startTime":"0","endTime":"0","summary":"Next generation Bria-OTS+ platform demonstrates rapid, potent and durable anti-cancer activity by activating both innate and adaptive immune responses Increased tumor cell cytotoxicity induced by both","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/11/07/3183561/0/en/BriaCell-Presents-Robust-Anti-Cancer-Activity-of-Bria-OTS-at-SITC-2025.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE0003795394.USD","BK4231","SITC","01308","IE00BYQNZ168.SGD","IE00B12V2V27.USD","IE00BYTNYN87.SGD","NCI","BK1103","SG9999011746.SGD","BK4080","BK1541","BCTX","BK4139","BK4202","IE0003851619.USD"],"gpt_icon":0},{"id":"2581100734","title":"Complete Tumor Regressions Observed in Preclinical Models with Co-administration of Cyncado’s A2B and A2A Receptor Antagonists and Cancer Vaccines","url":"https://stock-news.laohu8.com/highlight/detail?id=2581100734","media":"GlobeNewswire","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2581100734?lang=en_us&edition=fundamental","pubTime":"2025-11-07 20:00","pubTimestamp":1762516800,"startTime":"0","endTime":"0","summary":"Data from studies conducted by investigators at the National Cancer Institute at NCI laboratories, part of a multi-year research effort, will be presented at SITCDover, DE, Nov.  07, 2025  (GLOBE NEWS","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/11/07/3183521/0/en/Complete-Tumor-Regressions-Observed-in-Preclinical-Models-with-Co-administration-of-Cyncado-s-A2B-and-A2A-Receptor-Antagonists-and-Cancer-Vaccines.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4202","NCI"],"gpt_icon":0}],"pageSize":20,"totalPage":4,"pageCount":1,"totalSize":61,"code":"91000000","status":"200"}]}}